Loading data...
Loading data...
Analyzing the stock…
70
Gathering technical, fundamental, and market data — a few seconds
Health Care · ·
$71.69
▲ $1.29 (+1.8%)
Market data updated: 09/15 03:14 PM
Fundamentals updated: 09/15/2026
News analyzed: 09/15/2026
Market Cap
$1.75B
Day Range
$70.00 - $71.69
52-Week Range
$69.58 - $99.39
Beta
—
Next Earnings
05.11.2026
ANIP is a stock from the Healthcare sector — Pharmaceuticals, biotech, medical devices, and health insurance — less sensitive to economic cycles, but exposed to regulation and FDA approvals.
-28.0% (1Y)
Strengths: 8/31 factors positiveRisk: Medium
This score and all analysis on this page are for informational and educational purposes only and do not constitute investment advice. Read the full disclaimer
Weighted: Technical 25% · Fundamental 20% · Growth 15% · Valuation 15% · News 10% · Quality 10% · Risk 5%
Overall Score
🟡 Mixed
Technical Trend
🔴 Bearish
Insiders
🔴 Bearish
Computed directly from the same signals behind the score above — not AI-generated.
Biggest positive driver
DCF Fair Value
Estimated fair value: $204.90 vs. price $71.69 (+185.8%)
Fair Value
Biggest negative driver
Calmar Ratio (return vs. drawdown)
Calmar: 0.14 (3y annualized return 4.1% / max drawdown 29.0%)
Risk
What to watch next
When today echoes the past.
NO RELIABLE ECHO FOUND
Only 2 historical analog(s) found after removing overlapping dates — too few for a statistically meaningful comparison.
Historical matches considered: 2
TIME ECHO identifies historical situations that resemble the current market state. Historical outcomes are not guarantees of future performance. Similarity does not imply causation, and results may change as new data becomes available.
🗓️ What Changed This Week
🌱 Building History
We don't have a real data point from a week ago for this stock yet. The weekly comparison will appear once enough history has accumulated.
📊 Score History
53
Today
—
30D
—
90D
—
1Y
🐂🐻 Investment Thesis
🐂 Bull Case
🐻 Bear Case
🔍 What Could Prove This Wrong
This isn't a price-direction forecast — just a synthesis of real, already-computed data, and future conditions that could change the picture.
🧬 STOCK DNA
This stock's profile across 8 real dimensions — a research tool, not a recommendation
Growth
82
Quality
58
Value
62
Momentum
13
Risk
48
Sentiment
74
Fundamental
63
Institutional
0
Stocks with a similar DNA right now
This stock hasn't been analyzed by StockIQAI's movement engine yet — coverage is still expanding. Check back soon.
Recent media coverage of ANI Pharmaceuticals, Inc. has centered on its strategic shifts and investor scrutiny. The company announced Henry Gosebruch’s appointment to its board, highlighting his biopharmaceutical expertise as ANI positions itself as a rare disease-focused player. Analyst discussions during Q2 earnings emphasized stock performance—ANI’s modest 3% return over six months lagged behind broader market gains, raising questions about valuation and business stability. Investor watchlists debated whether its low valuation reflects undervaluation or underlying risks.
AI summary based on English-language news sources only — not investment advice.
Everyone's writing about ANI Pharmaceuticals, Inc.. News trend score: 74. Reason: 8 of the last 20 articles are positive, versus 4 negative.
News trend analysis is based on article sentiment only, and is not investment advice or financial counsel. Read the full disclaimer
🌡️ Emotional Temperature
15
🎯 Conviction (vs. Emotion)
42
Psychology
77
Fundamentals
63
Technical
13
Valuation
62
The price is holding at a real, documented historical support/resistance level (a 50-day high or low).
A significant decline over time, but on unusually low trading volume — holders unwilling to accept the loss.
A sharp drop, unusual volume, and negative news sentiment all at once — selling pressure that looks emotional.
Extreme momentum, price far above its moving average, and a large premium over fair value.
Price, volume, and sentiment accelerating together — a sign investors are chasing the price, not just following it.
Price (3M)
-15%
Market Narrative
35
Fundamental Reality
42
Narrative Gap
-7
🔀 Psychology Acceleration
News attention/sentiment is running well ahead of the price move itself.
🧠 StockIQ Psychologist
The market behavior for ANIP suggests traders are anchored near a critical support level (0.2% above), while loss aversion (38) hints at hesitation to exit despite recent underperformance. Herding (47) may be active as the stock lags peers, but FOMO and panic remain muted due to weak momentum and neutral volatility. The key open question is whether traders will break free from the support anchor or double down, given the narrative gap (-8) favoring reality over sentiment. The dominant anchoring effect could shift if volume spikes or price moves decisively.
Updated: 09/04/2026, 10:32 PM
What could change this?
👥 What the crowd believes
"‘low valuation multiples for value stocks... potentially deteriorating business models’ (Article 2)"
"‘posted a middling return of 3%... fell short of the S&P 500’s 11.7% gain’ (Article 4)"
"‘small-cap stocks... face steeper challenges in scaling their businesses’ (Article 6)"
"‘appointment strengthens board as ANI accelerates transformation’ (Article 8)"
📈 3D Investor Psychology
Signal classification confidence: High (confidence in the behavioral read, not a price prediction). Describes observable market behavior, not what any individual investor thinks, and is not a buy/sell signal.
🏛️ Investor DNA — Historical Investors
A Historical Strategy Simulation: assuming each investor follows their documented principles, how would they rate this stock today? This is not a prediction of what they would actually do.
🟢 Best match
Peter Lynch — 94/100
🔴 Weakest match
Jesse Livermore — 10/100
🗣️ Why do they disagree?
The methodologies for ANIP show a striking divide between bullish and bearish perspectives, reflecting starkly different investment philosophies. Samuel Armstrong Nelson and Peter Lynch, both growth-oriented, rate it near-perfectly (98 and 94), seeing it as either oversold or undervalued relative to its growth potential. Meanwhile, the value-focused Benjamin Graham (both Defensive and Enterprising Investor) and Jesse Livermore—who prioritizes trend alignment—reject it outright (31 and 10), dismissing it as either too expensive or counter-trend. Moderate approaches like Howard Marks (cycle) and Morgan Housel lean cautiously positive (74 and 62), suggesting it’s holdable but not a slam dunk, while the efficient-market camp (Malkiel/Bogle) and Jack Schwager remain neutral (55 and 51), questioning whether active selection adds value. The contrast highlights how ANIP’s valuation and momentum appeal to growth hunters but clashes with strict value or trend-following rules.
Peter Lynch
One Up on Wall Street (1989)
🟢 94
Growth candidate — the price hasn't caught up to the growth
Key question
Is the growth worth the price?
Fact → Principle → Simulation
Samuel Armstrong Nelson
The ABC of Stock Speculation (1903)
🟢 94
Cycle position looks favorable — closer to oversold than overbought
Key question
Is the price overextended, or is there still room to move?
Fact → Principle → Simulation
Charles Mackay
Extraordinary Popular Delusions and the Madness of Crowds (1841)
🟢 88
No obvious signs of crowd mania
Key question
Am I being swept along with the crowd, or thinking for myself?
Fact → Principle → Simulation
Philip Fisher
Common Stocks and Uncommon Profits (1958)
🟢 79
Exceptional company quality by Fisher's standards
Key question
How exceptional is this business, really?
Fact → Principle → Simulation
Howard Marks (Market Cycle)
Mastering the Market Cycle (2018)
🟢 76
Looks early-to-mid cycle, not overextended
Key question
Where are we in the cycle right now — near a hot extreme, or a cold one?
Fact → Principle → Simulation
Howard Marks
The Most Important Thing (2011) / Mastering the Market Cycle (2018)
🟢 73
Risk appears reasonably priced — no obvious cycle-timing red flag
Key question
What is the market probably misunderstanding about the risk here?
Fact → Principle → Simulation
Walter Bagehot
Lombard Street (1873)
🟢 72
Strong liquidity — would likely survive a real credit squeeze
Key question
Does this company have enough liquidity to survive real stress?
Fact → Principle → Simulation
Thorstein Veblen
The Theory of Business Enterprise (1904)
🟢 65
Growth appears aligned with real value creation
Key question
Is management building real value, or just building itself?
Fact → Principle → Simulation
Edgar Lawrence Smith
Common Stocks as Long-Term Investments (1924)
🟢 65
Looks like a real 'buy and hold for a decade' candidate
Key question
Is this a stock I'd be happy to hold and forget about for a decade?
Fact → Principle → Simulation
Morgan Housel
The Psychology of Money (2020)
🟡 64
Moderate — holdable, but not effortless
Key question
Could I live with this volatility long enough for compounding to actually work?
Fact → Principle → Simulation
Benjamin Graham
Security Analysis (1934) / The Intelligent Investor (1949)
🟡 60
Mixed — doesn't clearly pass Graham's tests
Key question
Where is my margin of safety?
Fact → Principle → Simulation
Gerald M. Loeb
The Battle for Investment Survival (1935)
🟡 58
Moderate risk to capital
Key question
How much capital could I lose here if I'm wrong?
Fact → Principle → Simulation
Burton Malkiel & John Bogle
A Random Walk Down Wall Street (1973) / The Little Book of Common Sense Investing (2007)
🟡 55
Mixed case — the evidence for picking this stock over an index is not strong
Key question
Do I actually have an edge here, or do I just think I do?
Fact → Principle → Simulation
Jack Schwager
Market Wizards (1989)
🟡 47
No clear edge either way
Key question
What's the risk/reward here, and where is my exit point?
Fact → Principle → Simulation
Benjamin Graham (Enterprising Investor)
The Intelligent Investor (1949) — the Enterprising Investor chapters
🔴 31
Not statistically cheap enough for the Enterprising Investor's looser safety bar
Key question
Is the stock statistically cheap enough to justify the extra risk?
Fact → Principle → Simulation
Jesse Livermore
Reminiscences of a Stock Operator (1923) / How to Trade in Stocks (1940)
🔴 10
Negative trend — against Livermore's core rule of trading with the trend
Key question
What is the price telling me right now?
Fact → Principle → Simulation
Based on the last 276 trading days, calculated from real price data. Click an indicator for details and a chart.
🔴 Most indicators support a downtrend (0 bullish · 10 bearish · 1 neutral)
A market-structure read based purely on real price and volume data — not full classic Wyckoff schematic identification (Phase A-E), but a quantitative analysis of what can reliably be computed: trading ranges, "effort vs. result", volume within the range, and Spring/Upthrust detection.
The stock is in a clear downtrend with no defined trading range in the period examined.
Medium confidence
The Wyckoff Method, developed by Richard Wyckoff in the early 20th century, reads the balance of supply and demand through price and volume, based on the premise that large investors ("smart money") quietly accumulate shares before rallies and quietly distribute them before declines. The read here is based solely on real price and volume data — full, precise identification of classic Wyckoff patterns (such as Phases A-E) requires human chart-reading experience and judgment, so this is an approximate algorithmic read, not a substitute for professional analysis. This should not be considered investment advice.
Gross Margin
—
Operating Margin
12.6%
Net Margin
8.9%
EBITDA Margin
22.9%
ROE
14.5%
ROA
5.4%
ROIC
—
EPS
$3.50
Cash
$285.58M
Total Debt
$309.11M
Current Ratio
2.71
Debt/Equity
0.57
How is Fair Value calculated? →
Current Price
$71.69
Estimated Fair Value (DCF)
$204.90
Model estimate — not a price target. Highly sensitive to growth/discount-rate assumptions.
Gap
+185.8%
🟢 Appears cheap relative to estimated value
Year 1 Growth Rate
25.0%
Discount Rate (WACC)
9.0%
Terminal Growth Rate
2.5%
Projection Years
5
| Year | Growth Rate | Projected FCF | Present Value |
|---|---|---|---|
| 1 | 25.0% | $214.24M | $196.55M |
| 2 | 19.4% | $255.75M | $215.26M |
| 3 | 13.8% | $290.91M | $224.64M |
| 4 | 8.1% | $314.55M | $222.83M |
| 5 | 2.5% | $322.41M | $209.55M |
Base FCF (last actual year)
$171.39M
Terminal Value
$5.08B
Present Value of Terminal Value
$3.30B
Enterprise Value
$4.37B
Net Debt
$23.52M
Equity Value
$4.35B
*The DCF model is an estimate based on assumptions — not a guaranteed forecast. You can change the assumptions to examine different scenarios.
Book Value per Share
$25.47
Tangible Book Value per Share (Tangible NAV)
-$0.06
Sentiment based on basic keywords (not AI) — 8 positive, 8 neutral, 4 negative out of the last 20 articles.
SeekingAlpha · 14.9.2026
Yahoo · 4.9.2026
Simply Wall St. · 4.9.2026
GlobeNewswire · 3.9.2026
Yahoo · 1.9.2026
StockStory · 1.9.2026
Yahoo · 27.8.2026
StockStory · 27.8.2026
Yahoo · 24.8.2026
StockStory · 24.8.2026
Yahoo · 24.8.2026
GlobeNewswire · 24.8.2026
StockStory · 16.8.2026
StockStory · 15.8.2026
Zacks · 14.8.2026
Zacks · 14.8.2026
Motley Fool · 14.8.2026
StockStory · 11.8.2026
Zacks · 10.8.2026
Benzinga · 10.8.2026
ANI Pharmaceuticals, Inc. (ANIP) currently has a StockIQ AI score of 53/100, rated "Moderate". The score is a weighted average across up to 7 categories (technical, fundamental, growth, fair value, news, quality, risk), based on real data only.
ANIP currently scores 53/100 (Moderate) across the categories we measure. StockIQ doesn't give buy/sell recommendations — use this as one data point in your own research, not as investment advice.
Per StockIQ's DCF model, ANIP's estimated fair value is $204.90, which is 185.8% above the current price of $71.69. This is one valuation model among several signals in the fair-value category, not a price target.
ANIP's technical score is 13/100, which currently reads as bearish — based on real price/volume signals (moving averages, RSI, MACD, and more), not a prediction of what happens next.
Based on the real signals StockIQ computed: Estimated fair value: $204.90 vs. price $71.69 (+185.8%); Revenue growth (last year): 43.8%; Earnings per share (EPS) growth: 419.2%.
Based on the real signals StockIQ computed: Calmar: 0.14 (3y annualized return 4.1% / max drawdown 29.0%); Price is below the 50-day average; Price is below the 200-day average.
StockIQ has no recorded dividend payment history for ANIP.
Real transactions by officers and insiders, as reported to the SEC on Form 4 — 0 purchases and 16 sales out of the last 25 filings.
| Name | Transaction Type | Date | Shares | Change | Price |
|---|---|---|---|---|---|
| CAREY STEPHEN P. | Open Market Sale | 31.8.2026 | 2,850 | -2,850 | $72.80 |
| Lalwani Nikhil | Open Market Sale | 25.8.2026 | 344,489 | -5,400 | $74.30 |
| Lalwani Nikhil | Open Market Sale | 25.8.2026 | 5,400 | -5,400 | $74.30 |
| Gosebruch Henry O | Grant/Award from Employer | 19.8.2026 | 6,662 | +6,662 | — |
| Gosebruch Henry O | Grant/Award from Employer | 19.8.2026 | 6,662 | +6,662 | — |
| Cook Meredith | Open Market Sale | 13.8.2026 | 500 | -500 | $75.48 |
| Gutwerg Ori | Open Market Sale | 10.8.2026 | 3,162 | -3,162 | $77.00 |
| CAREY STEPHEN P. | Open Market Sale | 29.7.2026 | 2,850 | -2,850 | $81.36 |
| CAREY STEPHEN P. | Open Market Sale | 29.7.2026 | 174,693 | -2,850 | $81.36 |
| Cook Meredith | Tax Withholding in Shares | 18.7.2026 | 2,466 | -2,466 | $79.20 |
| Cook Meredith | Tax Withholding in Shares | 18.7.2026 | 74,924 | -2,466 | $79.20 |
| Cook Meredith | Open Market Sale | 13.7.2026 | 500 | -500 | $81.84 |
| Cook Meredith | Open Market Sale | 13.7.2026 | 77,390 | -500 | $81.84 |
| CAREY STEPHEN P. | Exercise of Derivative Securities | 2.7.2026 | 3,313 | +3,313 | $49.51 |
| CAREY STEPHEN P. | Open Market Sale | 2.7.2026 | 3,313 | -3,313 | $86.00 |
| CAREY STEPHEN P. | Exercise of Derivative Securities | 2.7.2026 | 3,313 | -3,313 | $49.51 |
| CAREY STEPHEN P. | Exercise of Derivative Securities | 2.7.2026 | 180,856 | +3,313 | $49.51 |
| CAREY STEPHEN P. | Open Market Sale | 2.7.2026 | 177,543 | -3,313 | $86.00 |
| CAREY STEPHEN P. | Exercise of Derivative Securities | 2.7.2026 | 3,313 | -3,313 | $49.51 |
| CAREY STEPHEN P. | Open Market Sale | 29.6.2026 | 2,850 | -2,850 | $84.12 |
| Cook Meredith | Open Market Sale | 12.6.2026 | 500 | -500 | $82.03 |
| Cook Meredith | Open Market Sale | 12.6.2026 | 77,890 | -500 | $82.03 |
| HAUGHEY THOMAS | Open Market Sale | 8.6.2026 | 2,000 | -2,000 | $80.88 |
| HAUGHEY THOMAS | Open Market Sale | 8.6.2026 | 38,878 | -2,000 | $80.88 |
| CAREY STEPHEN P. | Exercise of Derivative Securities | 5.6.2026 | 183,705 | +3,312 | $49.51 |
Official FINRA data — the number of shares open in short positions, plus daily short-sale activity.
3,364,919 shares short as of 2026-08-31 · vs. 2,334,112 on 2026-07-31
Official biweekly report (FINRA Rule 4560) — no real higher-frequency data exists for this metric.
55.8% of trading volume this week was short selling, vs. 53.7% the prior week
Based on daily short-sale volume (Reg SHO) — a different metric from the open short interest above: this is daily trading volume, not an open position, so it updates weekly rather than biweekly.
Full breakdown of every data type and its source: Data Sources · Methodology